Diabetic retinopathy (DR) represents a major cause of visual impairment in developed countries. The ever-growing incidence of DR and its complications necessitates new strategies to screen patients, prevent complications and optimize management. For this reason, DR is a major target of AI-based models, especially those that can be used for large-scale screening.

AI models should recognize DR-related alterations, such as haemorrhages, exudates, cotton wool spots and neovascularization; and, starting from fundus images, establish the presence or absence of DR, and grade it according to the conventional DR grading scales.

The global Diabetic Retinopathy (DR) Artificial Intelligence Screening System market size is projected to grow from US$ 166 million in 2024 to US$ 7331 million in 2030; it is expected to grow at a CAGR of 88.0% from 2024 to 2030.

ReportPrime' newest research report, the “Diabetic Retinopathy (DR) Artificial Intelligence Screening System Industry Forecast” looks at past sales and reviews total world Diabetic Retinopathy (DR) Artificial Intelligence Screening System sales in 2022, providing a comprehensive analysis by region and market sector of projected Diabetic Retinopathy (DR) Artificial Intelligence Screening System sales for 2023 through 2029.

This Insight Report provides a comprehensive analysis of the global Diabetic Retinopathy (DR) Artificial Intelligence Screening System landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

This report also analyses the strategies of leading global companies with a focus on Diabetic Retinopathy (DR) Artificial Intelligence Screening System portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Diabetic Retinopathy (DR) Artificial Intelligence Screening System market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diabetic Retinopathy (DR) Artificial Intelligence Screening System and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity.

With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diabetic Retinopathy (DR) Artificial Intelligence Screening System.

Diabetes continues to rise throughout the United States and worldwide. Estimates show that the prevalence of diabetes mellitus will rise to 578 million people (10.2%) by the year 2030 and 700 million people (10.9%) by the year 2045. This increase in the prevalence of diabetes can also lead to a corresponding increase in diabetic complications, including nephropathy, cardiovascular disease, neuropathy, and retinopathy.

This report presents a comprehensive overview, market shares, and growth opportunities of Diabetic Retinopathy (DR) Artificial Intelligence Screening System market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Hardware
• Software

Segmentation by Application:

• Medical Institutions
• Great Health Scene

Market by Region:

• Americas
• APAC
• Europe
• Middle East & Africa

Company's Coverage:

• Airdoc Technology
• Digital Diagnostics
• Eyenuk
• RetinaLyze System
• Optomed
• Sibionics Technology
• Aeye Health
• VUNO
• Medimaging Integrated Solution
• EyRIS (SELENA+)
• Vistel
• RETINA-AI Health
• Acer Medical

Key Questions Addressed in this Report: